Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
about
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?Golimumab for moderate to severe ulcerative colitis.
P2860
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Short-term effectiveness of go ...... servational multicenter study.
@en
Short-term effectiveness of go ...... servational multicenter study.
@nl
type
label
Short-term effectiveness of go ...... servational multicenter study.
@en
Short-term effectiveness of go ...... servational multicenter study.
@nl
prefLabel
Short-term effectiveness of go ...... servational multicenter study.
@en
Short-term effectiveness of go ...... servational multicenter study.
@nl
P2093
P2860
P50
P1476
Short-term effectiveness of go ...... bservational multicenter study
@en
P2093
Gloria Garcia
Jose Maria Paredes
Marga Muñoz
MariFe Garcia
Marisa Iborra
Nuria Maroto
Pedro Almela
P2860
P304
10432-10439
P356
10.3748/WJG.V22.I47.10432
P407
P577
2016-12-01T00:00:00Z